002723SZSE

2026 First Quarter Report

Xiaosong Co., Ltd.··10p

✨ AI Summary

This report details the 2026 first quarter financial performance. Operating income decreased by 43.76% to CNY 186,121,549.84. Net profit attributable to shareholders was a loss of CNY 30,044,664.92, a significant drop from the previous year. Total assets also saw a slight decrease of 4.02% to CNY 1,479,991,730.91.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openaiSign In to Upgrade

Important Content Reminder:

  1. The board of directors and senior management confirm that the contents of the quarterly report are true, accurate, and complete, with no false records, misleading statements, or major omissions.
  2. The person in charge of the company, the person in charge of accounting, and the person in charge of the financial department confirm that the financial information in the report is true, accurate, and complete.
  3. The first quarter report is subject to audit.
ItemCurrent PeriodSame Period Last YearChange (%)
Operating Income (CNY)186,121,549.84330,955,782.73-43.76
Net Profit Attributable to Shareholders of the Listed Company (CNY)-30,044,664.92-8,908,726.80-237.62
Net Profit Attributable to Shareholders of the Parent Company (CNY)-29,719,718.60-8,950,012.93-232.06
Operating Cash Flow (CNY)-17,929,334.72-7,810,608.06-129.55
Basic Earnings per Share (CNY)-0.0904-0.028-222.86
Diluted Earnings per Share (CNY)-0.0904-0.028-222.86
ItemCurrent PeriodSame Period Last YearChange (%)
Total Assets (CNY)1,479,991,730.911,541,902,040.64-4.02
Total Liabilities (CNY)733,719,853.82760,275,668.01-3.49

Non-Recurring Gains and Losses

ItemCurrent Period Amount (CNY)Description
Non-recurring gains and losses-464,687.53-
Other non-operating income125,172.39-
Government subsidies45,000.00-
Other non-recurring gains and losses-24,383.69-
Total-324,946.32-

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Notes & Comments

Sign in to leave a comment or private note.

Loading…